.Pharmacolibrary.Drugs.ATC.J.J04AD03

Information

Ethionamide is a second-line antitubercular agent used primarily for the treatment of multidrug-resistant tuberculosis (MDR-TB). It works by inhibiting mycolic acid synthesis, essential for the bacterial cell wall. It is used in combination with other antitubercular drugs and is still approved for clinical use, especially in resistant TB cases.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

1. Zhu, M, et al., & Peloquin, CA (2002). Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinburgh, Scotland) 82(2-3) 91–96. DOI:10.1054/tube.2002.0330 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12356460

2. Auclair, B, et al., & Peloquin, CA (2001). Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrobial agents and chemotherapy 45(3) 810–814. DOI:10.1128/AAC.45.3.810-814.2001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11181366

3. Nix, DE, et al., & Peloquin, CA (2004). Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinburgh, Scotland) 84(6) 365–373. DOI:10.1016/j.tube.2004.04.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15525560

Revisions

• 06/2025 initial generated model